Publications

Frankenfeld CL, Leslie TF, Menon NM. 2021. Longer time-to-treatment but better survival for colorectal cancer patients presumptively not diagnosed in a hospital. Cancer Causes Control 32:1185–1191.

Frankenfeld CL. 2021. Reduced rank regression: Illustration of an important tool in the evaluation of dietary patterns and chronic disease risk. J Nutr 151:3269–3270, https://doi.org/10.1093/jn/nxab331.

Rana ZH, Frankenfeld CL, de Jonge L, Kennedy EJ, Bertoldo J, Short JL, Cheskin LJ. 2021. Dietary intake and representativeness of a diverse college-attending population compared with an age-matched US population. Nutrients 13:3810, https://doi.org/10.3390/nu13113810.

Frankenfeld CL, Hakes JK, Leslie TF. 2021. All-cause mortality and residential racial and ethnic segregation and composition as experienced differently by individual-level race, ethnicity, and gender: Mortality Disparities in American Communities data. Ann Epidemiol 65:38-45, https://doi.org/10.1016/j.annepidem.2021.10.008.

Ankley GT, Berninger JP, Blackwell BR, Cavallin JE, Collette TW, Ekman DR, Fay KA, Feifarek DJ, Jensen KM, Kahl MD, Mosley JD, Poole ST, Randolph EC, Rearick D, Schroeder AL, Swintek J, Villeneuve DL. 2021. Pathway-based approaches for assessing biological hazards of complex mixtures of contaminants: A case study in the Maumee River. Environ Toxicol Chem 40:1090–1122.

Villeneuve DL, Blackwell BR, Cavallin JE, Cheng W, Feifarek DJ, Jensen KM, Kahl MD, Milsk RY, Poole ST, Randolph EC, Saari TW, Ankley GT. 2021. Case study in 21st Century ecotoxicology: Using in vitro aromatase inhibition data to predict short term in vivo responses in adult female fish. Environ Toxicol Chem 40:1155–1170.

Thompson CM, Bhat VS, Brorby GP, Haws LC. 2021. Development of updated RfD and RfC values for medium carbon range aromatic and aliphatic total petroleum hydrocarbon fractions. J Air Waste Manag Assoc 71(12):1555–1567, doi: 10.1080/10962247.2021.1974123.

Chappell GA, Wikoff DS, Thompson CM. 2021. Assessment of mechanistic data for hexavalent chromium-induced rodent intestinal cancer using the key characteristics of carcinogens. Toxicol Sci 180(1):38–50.

Chang Y, Huynh CTT, Bastin KM, Rivera BN, Siddens LK, Tilton SC. 2020. Classifying polycyclic aromatic hydrocarbons by carcinogenic potency using in vitro biosignatures. Toxicol in Vitro 69:104991, doi: 10.1016/j.tiv.2020.104991.

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198. doi: 10.14740/gr1167.

Bhat VS, Cohen SM, Gordon EB, Wood CE, Cullen JM, Harris MA, Proctor DM, Thompson CM. 2020. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: A case study with hexavalent chromium, captan, and folpet. Crit Rev Toxicol 50(8) (open access).

Parker J, Boles C, Leleck O, Buerger AN, Egnot N, Sunderman A, et al. 2020. Advancing toward normal operations for arenas and stadiums. Toxicol Ind Health 36(9):718–727.

Wikoff D, Lewis JR, Erraguntla N, Franzen A, Foreman J. 2020. Facilitation of risk assessment with evidence-based methods — A framework for use of systematic mapping and systematic reviews in determining hazard, developing toxicity values, and characterizing uncertainty. Regul Toxicol Pharmacol (in press), journal pre-press online.

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp (open access).

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.